September 8, 2026
Written by Vytautas Valinskas Key takeaways Two results, one week apart, and very different evidence On 26 August the US Food and Drug Administration approved Rasonque, the brand name for daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who have already had one systemic therapy or cannot take combination chemotherapy. One week […]
